Viridian Therapeutics, Inc.\DE VRDN

Rank #2360 · Nasdaq · $2.5B market cap

⚠ Going-concern flag — the auditor (KPMG LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

22.0

P/E

-10.7

P/B

6.44

ROE

-60.2%

Op. Margin

-81035.0%

Debt Ratio

18%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -10.7x, P/B 6.44x. Ranks in the top 78% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -60.2%. Ranks in the top 95% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 18%. Ranks in the top 12% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆

Poor

Revenue decline of 82.3% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2014	$0.0B	$-0.0B	$-0.0B	$-0.0B	-3.6	-115
2015	$0.0B	$-0.0B	$-0.0B	$0.0B	-105.9	35
2016	–	$-0.0B	$-0.0B	$0.0B	–	115
2017	–	$-0.0B	$-0.0B	$-0.0B	–	-21
2018	$0.0B	$-0.0B	$-0.0B	$-0.1B	-662.8	-23
2019	$0.0B	$-0.0B	$-0.0B	$0.0B	-394.5	38
2020	$0.0B	$-0.0B	$-0.0B	$0.1B	-941.0	28
2021	$0.0B	$-0.1B	$-0.1B	$0.0B	-10512.4	71
2022	$0.0B	$-0.1B	$-0.1B	$0.1B	-2690.8	13
2023	$0.0B	$-0.1B	$-0.1B	$0.1B	-2690.8	33
2024	$0.0B	$-0.1B	$-0.1B	$0.2B	-7579.2	26
2025	$0.0B	$-0.3B	$-0.2B	$0.4B	-81035.0	18

← See the full screener